A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions

Le résumé fourni par la source

Breast cancer (BC) is a powerful example of the intra- and interpatient heterogeneity of tumours; thus, there remain several grey areas in BC treatment approaches. This is especially true for advanced/metastatic disease (mBC) [ 1 , 2 , 3 ]. Organoid cultures are suitable models for studying the histological complexity and genetic heterogeneity of parental tumours and can be used to assess treatment strategies for challenging diseases such as mBC. Here, we report a proof-of-concept test case using organoid cultures from metastatic BC specimens to rapidly test drug sensitivity and molecular-lesion-driven treatments. Based on the relevant impact of PIK3CA gene mutations on breast cancer progression and resistance to therapy [ 4 ], we assessed the efficacy of alpelisib (BYL719; Novartis Pharma AG, Basel, Switzerland), a specific PI3K-α inhibitor, on organoid cultures derived from multisite mBC samples carrying specific PIK3CA gene mutations.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.